WITHDRAWN: Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain-Reference-Cited by-同舟云学术

WITHDRAWN: Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain

Published:2019 Issue: Volume:39 Page:100006
ISSN:1567-5688
Container-title:Atherosclerosis Supplements
language:en
Short-container-title:Atherosclerosis Supplements

Author:

Masana Luis,Ibarretxe Daiana,Rodríguez-Borjabad Cèlia,Plana Núria,Valdivielso Pedro,Pedro-Botet Juan,Civeira Fernando,López-Miranda Jose,Guijarro Carlos,Mostaza Jose,Pintó Xavier

Funder

Amgen

Sanofi

FERRER

Merck

MSD

RUBIO

ESTEVE

MYLAN

Sociedad Española de Arteriosclerosis

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Reference18 articles.

1. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society;Nordestgaard;Eur. Heart J.,2013

2. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study;Talmud;Lancet,2013

3. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

4. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

5. Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia;Landmesser;Eur. Heart J.,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019;Clínica e Investigación en Arteriosclerosis (English Edition);2019-05